U.S. Banks Stock News

In recent months, Ormat Technologies has outlined plans to add 149 MW of new capacity by the end of 2027, including 101 MW from geothermal projects, while committing US$180 million to build additional energy storage assets in the United States through 2028. This combination of geothermal expansion and sizable storage investment highlights Ormat’s effort to deepen its role in supplying grid-stable renewable power as adoption of clean energy accelerates. Next, we’ll explore how Ormat’s planned...

Why CNA Financial (CNA) Is Back in Focus After Its Latest Quarter CNA Financial (CNA) has drawn fresh attention after quarterly results came in below market expectations, with weaker core earnings per share and profitability despite growth in premiums and investment income. At the same time, management raised the regular dividend by 4% and announced a special dividend. This move highlights confidence in ongoing cash generation, even as underwriting performance and higher expenses remain key...

In the fourth quarter of 2025, Medpace Holdings reported a 32% year-over-year revenue increase, while Mairs & Power Small Cap Fund cited the company as a key contributor in its investor letter due to stronger clinical trial trends linked to GLP-1 programs. This combination of healthier trial cancellation patterns and momentum in GLP-1 research highlights how Medpace is benefiting from current demand in metabolic-related clinical development. We’ll now explore how this improved GLP-1-driven...

On March 24, 2026, Ardent Health, Inc. announced that Ethan Chernin departed the company and would no longer serve as President, Hospital Services, with his separation treated as a “Qualifying Termination” under the firm’s Executive Severance Plan. This leadership change in a core operating role raises important questions about continuity in hospital operations and the company’s broader execution plans. We’ll now examine how the sudden exit of Ardent’s President of Hospital Services may...

Amylyx Pharmaceuticals (AMLX) shares are in focus after the company reported that the final participant has been randomized and dosed in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycemia. See our latest analysis for Amylyx Pharmaceuticals. The latest trial milestone arrives as momentum in Amylyx Pharmaceuticals' share price has been building, with a 7 day share price return of 23.98% and a 90 day share price return of 39.02%, set against a very large 1 year...

AI is starting to reshape how healthcare is delivered, from spotting disease earlier to tailoring treatments and cutting wasted time in hospitals, just as energy driven inflation and higher yields keep pressure on costs worldwide. For investors, that mix of structural healthcare demand and AI driven efficiency tools offers exposure to a theme that is less tied to short term swings in consumer spending or manufacturing cycles. This article walks through 3 stocks from our Transformative AI...

Recent analysis of past performance shows that Service Corporation International has not increased the number of funeral services performed over the last two years, while also reporting weaker free cash flow margins and a declining return on invested capital compared with sector expectations. This combination of stagnant service volumes and deteriorating profitability metrics suggests the company may be contending with demand constraints and limited high-return reinvestment...

Helmerich & Payne has completed the sale of Tulsa’s Utica Square retail center, with after-tax proceeds exceeding its US$100 million divestiture target and earmarked largely to retire the company’s remaining term loan as part of a balance sheet-focused portfolio review. The move marks a significant shift away from non-core real estate and frees up financial capacity that can be redeployed toward Helmerich & Payne’s core drilling and technology operations following its capital-intensive KCA...

Acuity (AYI) is back in focus after its second quarter 2026 earnings, where adjusted earnings per share came in ahead of expectations while revenue lagged forecasts, highlighting contrasting trends across its Lighting and Intelligent Spaces businesses. See our latest analysis for Acuity. The share price reaction has been mixed, with a 1 day share price return of 1.06% after earnings but a 90 day share price return representing a 28.55% decline. However, the 3 year total shareholder return of...

Xeris Biopharma Holdings (XERS) drew fresh investor attention after reporting fourth quarter 2025 earnings per share of US$0.06 on revenue of US$85.8 million, both above prior projections and supported by a reiteration of positive analyst views. See our latest analysis for Xeris Biopharma Holdings. At a share price of US$6.05, Xeris Biopharma’s recent 8.04% 7 day share price return and 4.13% 30 day share price return contrast with a 17.69% decline year to date. At the same time, the 37.19% 1...

Olin Corporation recently received an upgrade from Wells Fargo, with the firm citing expectations of stronger margins in its electrochemical operations supported by higher caustic soda prices and stable North American natural gas costs. This shift in analyst view highlights how Olin’s earnings outlook is increasingly being tied to both its cost position and evolving global chemical pricing shaped by geopolitical tensions. We’ll now examine how this margin-focused upgrade from Wells Fargo...

Assurant recently reported its ninth consecutive year of profitable growth, highlighted by strong Q4 2025 earnings, record mobile trade-in activity, and the launch of Assurant Home Warranty through a partnership with Compass International Holdings, expanding its reach in the real estate channel. These developments underline how Assurant’s diversified protection offerings and new distribution partnerships are reinforcing its position across connected devices, housing, and broader lifestyle...

In recent weeks, Tandem Diabetes Care has faced an extended losing streak and a reduction in its market value, amid investor concerns about its operating performance and financial health. Adding to this pressure, JPMorgan Chase & Co. cut its stake in the company by more than a third, underscoring shifting institutional confidence at a sensitive time. Now we’ll examine how weakening operating performance and JPMorgan’s reduced stake may influence Tandem Diabetes Care’s existing investment...

Recent Performance Snapshot Federal Signal (FSS) has attracted fresh attention after a strong 1 year total return of 55.23%, contrasting with a modest month gain of 0.31% and a 4.72% decline over the past 3 months. See our latest analysis for Federal Signal. The 1 year total shareholder return of 55.23% stands in contrast to the recent 4.72% 3 month share price decline and slightly negative year to date share price return, suggesting that momentum has cooled following a strong multi year...

How Four Corners Property Trust Stock Has Been Performing Four Corners Property Trust (FCPT) has drawn attention after recent trading, with the stock closing at $23.44 and showing mixed return patterns over the past week, month and past 3 months. Over the past day, FCPT recorded a 1.31% decline, with a 1.97% decline across the last week and an 8.72% decline over the past month. The past 3 months have been relatively flat, with a total return of 0.21%. Looking at a slightly longer horizon, the...

In early April 2026, Intellia Therapeutics received an upgrade from Jones Trading after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, restoring regulatory clarity following a patient death deemed likely unrelated to the company’s treatment. This renewed regulatory confidence, alongside expectations for key HAELO Phase 3 data, highlights how safety assessments can critically reshape perceptions of Intellia’s CRISPR pipeline and commercial pathway. With clinical...

In early April 2026, Prestige Consumer Healthcare faced pressure after regulatory scrutiny, including FTC concerns over industry consolidation and a federal healthcare fraud crackdown, weighed on sentiment around its over-the-counter product portfolio. Beyond the immediate regulatory overhang, the episode highlights how sector-wide oversight can quickly reshape market perceptions of risk around even established healthcare brands. Against this backdrop of intensified regulatory attention,...

In the past quarter, Matson reported a strong fourth quarter with revenue slightly above analyst expectations, helped by higher freight rates and volumes on its China service as e-commerce and electronic goods demand remained robust. An interesting aspect of this result is that Ocean Transportation operating income nearly matched the prior year’s level despite lower overall revenue, highlighting how mix and pricing in the China service supported profitability. We’ll now examine how the...

EverCommerce recently reported its Q4 results and issued guidance for Q1 and the 2026 fiscal year, prompting a strong reaction against a backdrop of geopolitical uncertainty. The fresh guidance has sharpened investor focus on how EverCommerce’s execution in its core SaaS and payments offerings may align with earlier expectations. Now we’ll explore how EverCommerce’s latest earnings and guidance update could reshape its investment narrative built around SaaS and payments. AI is about to...

Tecnoglass recently expanded its share repurchase authorization to US$250 million and outlined a 2026 revenue outlook of US$1.06–1.13 billion, alongside margin-protection measures and ongoing geographic expansion plans. This combination of a larger buyback and quantified multi-year growth ambitions highlights management’s focus on capital return while underpinning long-term operating visibility. Next, we’ll examine how Tecnoglass’s expanded US$250 million share repurchase authorization could...

Pilgrim’s Pride recently launched a cash tender offer to repurchase up to US$250 million of its 6.250% Senior Notes due 2033 while simultaneously receiving shareholder proposals on political spending transparency and diversity reporting ahead of its April 29, 2026 annual meeting. The company’s opposition to these governance and disclosure proposals, alongside the debt repurchase, highlights management’s current priorities between balance sheet management and broader environmental, social,...

In early April 2026, National Energy Services Reunited secured roughly US$300 million of multi-year cementing contracts across Kuwait and several North African markets, while analysts reiterated positive recommendations on the stock amid encouraging operational updates at the Jafurah project. This combination of fresh long-term contracts and upbeat sector commentary strengthens the company’s positioning in core Middle East and North Africa oilfield services, reinforcing expectations for more...

Donaldson Company (DCI) is in focus after its fiscal Q2 2026 earnings call highlighted record sales across all three business segments and an updated outlook that management described as confident. See our latest analysis for Donaldson Company. At a share price of $85.54, Donaldson’s recent Q2 update and the Facet acquisition come after a mixed stretch, with a 7 day share price return of 3.6% versus a 30 day share price decline of 3.6%, while the 1 year total shareholder return of 45.0%...

O'Reilly Automotive (ORLY) has quietly stayed on many investors’ watchlists, with the stock showing mixed short term performance, including a small 1 day gain and a negative move over the past month. See our latest analysis for O'Reilly Automotive. At around US$92.13, the share price has been steady in the near term, with a modest 90 day share price return of 1.93% sitting against a 1 year total shareholder return of 3.61% and a 5 year total shareholder return of 165.98%, which hints that...